Pembrolizumab could extend survival for prostate cancer ‘super responders’

Researchers have discovered that a small proportion of men with end-stage prostate cancer respond to the immunotherapy Keytruda™ (pembrolizumab), with some gaining years of extra life. Research led by The Institute of Cancer Research and The Royal Marsden Foundation Trust (both London, UK) has observed that one in 20 men with end-stage prostate cancer responded well to Keytruda® (pembrolizumab) despite having a very poor prognosis before treatment. The study has been published in the Journal of Clinical Oncology. The Phase II clinical trial involved 258 men with advanced prostate cancer who had relapsed and become resistant to previous therapies. In...